7 results on '"Gabriella Gainaru"'
Number of results to display per page
Search Results
2. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
- Author
-
Themis Karmiris, Zois Mellios, Maria Kotsopoulou, Konstantinos Anargyrou, George Karianakis, Eleftheria Hatzimichael, Gerassimos A. Pangalis, Phivi Rondogianni, Evangelos Terpos, Stamatios Karakatsanis, Argyris Symeonidis, Theodoros P. Vassilakopoulos, Eirini Katodritou, Pavlina Konstantinidou, Catherine Mainta, Pantelis Tsirkinidis, Sotirios G. Papageorgiou, Theoni Leonidopoulou, Panagiotis Tsirigotis, Ioannis Kotsianidis, Christina Kalpadakis, Ioannis Datseris, Evridiki Michali, Marie-Christine Kyrtsonis, Anna Pigaditou, Maria K. Angelopoulou, Eleni Variamis, Maria Dimou, Helen A. Papadaki, Meletios-Athanassios Dimopoulos, Maria Arapaki, Effimia Vrakidou, Gabriella Gainaru, Paraskevi Roussou, Vassiliki Pappa, Vassilios Prassopoulos, Christos Poziopoulos, Marina P. Siakantaris, Theodora Assimakopoulou, S. Chatziioannou, Elissavet Vervessou, Dimitrios Boutsis, Kostas Konstantopoulos, Evdoxia Chatziharissi, Maria Papaioannou, Maria Palassopoulou, Chryssa Vadikolia, Maria Tsirogianni, Panayiotis Panayiotidis, and Sotirios Sachanas
- Subjects
PET-CT ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Mediastinum ,Retrospective cohort study ,Hematology ,General Medicine ,CHOP ,medicine.disease ,Lymphoma ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Positron emission tomography ,030220 oncology & carcinogenesis ,medicine ,Rituximab ,Radiology ,business ,030215 immunology ,medicine.drug - Abstract
End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the prognostic significance of EoT-PET/CT after adequate response to R-CHOP. Among 231 consecutive PMLBCL patients, 182 underwent EoT-PET/CT and were evaluated according to the Deauville 5-point scale (D5PS) criteria. Freedom from progression (FFP) was measured from the time of PET/CT examination. Among 182 patients, 72 (40%) had D5PS score 1 (D5PSS-1), 33 (18%) had 2, 28 (15%) had 3, 29 (16%) had 4, and 20 (11%) had 5. The 5-year FFP was 97, 94, 92, 82, and 44% for D5PSS-1, D5PSS-2, D5PSS-3, D5PSS-4, and D5PSS-5, respectively. Among 105 patients with unequivocally negative PET/CT (D5PSS-1/D5PSS-2), 49 (47%) received RT (median dose 3420 cGy) and 56 (53%) did not with relapses in 0/49 vs. 4/56 patients (2 mediastinum and 2 isolated CNS relapses).The 5-year FFP for those who received RT or not was 100% versus 96%, when isolated CNS relapses were censored (p = 0.159). Among D5PSS-3 patients (27/28 irradiated-median dose 3600 cGy), the 5-year FFP was 92%. The 5-year FFP for D5PSS-4 and D5PSS-5 was 82 and 44%; 44/49 patients received RT (median dose 4000 and 4400 cGy for D5PSS-4 and D5PSS-5). Our study supports the omission of RT in a sizeable fraction of PET/CT-negative patients and definitely discourages salvage chemotherapy and ASCT in patients with PMLBCL who conventionally respond to R-CHOP, solely based on PET/CT positivity in the absence of documented progressive or multifocal disease. The persistence of positive PET/CT with D5PSS < 5 after consolidative RT should not trigger the initiation of further salvage chemotherapy in the absence of conventionally defined PD.
- Published
- 2021
3. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP
- Author
-
Konstantinos Anargyrou, George Karianakis, Maria Kotsopoulou, Eleftheria Hatzimichael, Pavlina Konstantinidou, Maria Papaioannou, Chryssa Vadikolia, Evangelos Terpos, Katerina Megalakaki, Lydia Kyriazopoulou, Stamatios Karakatsanis, Anna Pigaditou, Theoni Leonidopoulou, Maria Dimou, Eleni Variamis, Michail Michail, Dimitrios Boutsis, Effimia Vrakidou, Gabriella Gainaru, Pantelis Tsirkinidis, Ioannis Kotsianidis, Kostas Konstantopoulos, Paraskevi Roussou, Maria N. Dimopoulou, Maria Palassopoulou, Theodora Assimakopoulou, Panayiotis Tsirigotis, Christina Kalpadakis, Maria K. Angelopoulou, Gerasimos Tsourouflis, Vassiliki Pappa, Evdoxia Hatjiharissi, Sotirios G. Papageorgiou, Theophanis Economopoulos, Themis Karmiris, Argyris Symeonidis, Meletios-Athanasios Dimopoulos, Christos Poziopoulos, Eirini Katodritou, Ekaterini Stefanoudaki, Panayiotis Zikos, Helen A. Papadaki, Marina P. Siakantaris, Theodoros P. Vassilakopoulos, G. Kourti, Maria Tsirogianni, Gerassimos A. Pangalis, Eurydiki Michalis, Panayiotis Panayiotidis, Sotirios Sachanas, Elissavet Vervessou, Marie-Christine Kyrtsonis, and Fotios Panitsas
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Hematologic Malignancies ,CHOP ,Gastroenterology ,Extranodal Disease ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Internal medicine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,EPOCH (chemotherapy) ,Extranodal Involvement ,Cyclophosphamide ,business.industry ,medicine.disease ,Prognosis ,Lymphoma ,Oncology ,Doxorubicin ,Vincristine ,030220 oncology & carcinogenesis ,Prednisone ,Rituximab ,Lymphoma, Large B-Cell, Diffuse ,business ,030215 immunology ,medicine.drug - Abstract
Background R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective but also more toxic than R-CHOP. Reliable prognostic classification is needed to guide treatment decisions. Materials and Methods We analyzed the impact of clinical prognostic factors on the outcome of 332 PMLBCL patients ≤65 years treated with R-CHOP ± radiotherapy in a multicenter setting in Greece and Cyprus. Results With a median follow-up of 69 months, 5-year freedom from progression (FFP) was 78% and 5-year lymphoma specific survival (LSS) was 89%. On multivariate analysis, extranodal involvement (E/IV) and lactate dehydrogenase (LDH) ≥2 times upper limit of normal (model A) were significantly associated with FFP; E/IV and bulky disease (model B) were associated with LSS. Both models performed better than the International Prognostic Index (IPI) and the age-adjusted IPI by Harrel's C rank parameter and Akaike information criterion. Both models A and B defined high-risk subgroups (13%–27% of patients [pts]) with approximately 19%–23% lymphoma-related mortality. They also defined subgroups composing approximately one-fourth or one-half of the patients, with 11% risk of failure and only 1% or 4% 5-year lymphoma-related mortality. Conclusion The combination of E/IV with either bulky disease or LDH ≥2 times upper limit of normal defined high-risk but not very-high-risk subgroups. More importantly, their absence defined subgroups comprising approximately one-fourth or one-half of the pts, with 11% risk of failure and minimal lymphoma-related mortality, who may not need more intensive treatment such as R-da-EPOCH. Implications for Practice By analyzing the impact of baseline clinical characteristics on outcomes of a large cohort of patients with primary mediastinal large B-cell lymphoma homogeneously treated with R-CHOP with or without radiotherapy, we developed novel prognostic indices which can aid in deciding which patients can be adequately treated with R-CHOP and do not need more intensive regimens such as R-da-EPOCH. The new indices consist of objectively determined characteristics (extranodal disease or stage IV, bulky disease, and markedly elevated serum lactate dehydrogenase), which are readily available from standard initial staging procedures and offer better discrimination compared with established risk scores (International Prognostic Index [IPI] and age-adjusted IPI).
- Published
- 2020
4. PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) ± RADIOTHERAPY (RT)
- Author
-
Ioannis Kotsianidis, Paraskevi Roussou, Dimitrios Boutsis, Gerasimos Pangalis, Eirini Katodritou, Pavlina Konstantinidou, M.A. Dimopoulos, Konstantinos Anargyrou, Anna Pigaditou, Maria Kotsopoulou, E. Hadjiharissi, Evridiki Michali, Ekaterini Stefanoudaki, Argyris Symeonidis, Sotirios G. Papageorgiou, Vassiliki Pappa, P. Panayitidis, George Karianakis, Themistoklis Karmiris, Eleni Variami, Chryssa Vadikolia, Christos Poziopoulos, Theoni Leonidopoulou, Maria Tsirogianni, G. Kourti, Michail Michail, Sotirios Sachanas, Konstantinos Konstantopoulos, Maria Papaioannou, Effimia Vrakidou, T.P. Vassilakopoulos, Gabriella Gainaru, Maria K. Angelopoulou, Christina Kalpadakis, and E. Terpos
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Hematology ,General Medicine ,CHOP ,Radiation therapy ,Internal medicine ,medicine ,Primary Mediastinal Large B-Cell Lymphoma ,Rituximab ,business ,medicine.drug - Published
- 2019
5. PF297 COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)
- Author
-
T. Giannikos, Konstantinos Konstantopoulos, E. Constaninou, A. Liaskas, K. Sakellariou, Z. Mellios, I. Assimakopoulos, M. Bellia, D. Grentzelias, George Karianakis, T.P. Vassilakopoulos, Gabriella Gainaru, Themistoklis Karmiris, E. Katrodritou, Eleni Plata, Theoni Leonidopoulou, Sotirios G. Papageorgiou, Theodora Assimakopoulou, Eleni Papadaki, V. Xanthopoulos, Maria Tsirogianni, Stamatios Karakatsanis, P. Katsaouni, H. Giatra, Chrysovalantou Chatzidimitriou, Maria K. Angelopoulou, Christina Kalpadakis, Argyris Symeonidis, Vassiliki Pappa, Evgenia Verigou, Maria Arapaki, G. Kourti, and M. Bakiri
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,R-CHOP chemotherapy ,medicine ,Rituximab ,Primary Mediastinal Large B-Cell Lymphoma ,Hematology ,EPOCH (chemotherapy) ,CHOP ,business ,medicine.drug - Published
- 2019
6. PS1089 PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE
- Author
-
E. Plata, Z. Mellios, Evgenia Verigou, C. Kalpadakis, Gabriella Gainaru, S. Karatsanis, K. Themistoklis, Eleni Papadaki, I. Datseris, K. Konstantopoulos, Maria Arapaki, K. Sakellariou, D. Grentzelias, Theodoros P. Vassilakopoulos, Sotirios G. Papageorgiou, T. Giannikos, G. Karanakis, E. Katodritou, A. Koumarianou, S. Chatziioannou, M. Bakiri, Chrysovalantou Chatzidimitriou, V. Xanthopoulos, M. Efstathopoulou, V. Prassopoulos, P. Rontogianni, M. K. Angelopoulou, H. Giatra, Maria Tsirogianni, and A. Simeonidis
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,Rituximab ,Primary Mediastinal Large B-Cell Lymphoma ,Hematology ,EPOCH (chemotherapy) ,Radiology ,business ,medicine.drug - Published
- 2019
7. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens
- Author
-
Pagona Flevari, Maria N. Dimopoulou, Xanthoula Yiakoumis, Konstas Konstantopoulos, Kyriaki Petevi, Gabriella Gainaru, Maria Dimou, Panayiotis Tsaftaridis, Eleni Plata, Nora-Athina Viniou, Alexandros Kanellopoulos, George Boutsikas, Katerina Koutsi, Loula Papageorgiou, John Meletis, Panayiotis Panayiotidis, Sotirios Sachanas, Pantelis Tsirkinidis, Maria K. Angelopoulou, Eleni Variami, Gerassimos A. Pangalis, Vassilios Telonis, Maria Moschogiannis, Marie-Christine Kyrtsonis, Marina P. Siakantaris, and Theodoros P. Vassilakopoulos
- Subjects
musculoskeletal diseases ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Adolescent ,Lymphocyte ,Dacarbazine ,Hematologic Malignancies ,Bleomycin ,Vinblastine ,Gastroenterology ,Monocytes ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,0302 clinical medicine ,Monocytosis ,Internal medicine ,Lymphopenia ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Doxorubicin ,Lymphocyte Count ,Lymphocytes ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Middle Aged ,medicine.disease ,Hodgkin's lymphoma ,Combined Modality Therapy ,Hodgkin Disease ,medicine.anatomical_structure ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Female ,Lymphocytopenia ,business ,030215 immunology ,medicine.drug - Abstract
Low absolute lymphocyte count (ALC) to absolute monocyte count (AMC) ratio (ALC/AMC) is an independent prognostic factor in Hodgkin lymphoma (HL), but different cutoffs (1.1, 1.5, and 2.9) have been applied. We aimed to validate the prognostic significance of ALC/AMC in 537 homogenously treated (doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalents ± radiotherapy) classical HL patients at various cutoffs. The median ALC/AMC was 2.24 (0.44–20.50). The median AMC was 0.653 × 109/L (0.050–2.070). Lower ALC/AMC was associated with established markers of adverse prognosis. In total, 477 (89%), 418 (78%), and 189 (35%) patients had an ALC/AMC ratio of ≥1.1, ≥1.5, and ≥2.9; respectively; 20% had monocytosis (≥0.9 × 109/L). Ten-year time to progression (TTP) was 77% versus 55% for patients with ALC/AMC ≥1.1 and
- Published
- 2016
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.